Based on the documented need for additional education in prostate cancer, bladder cancer, and kidney cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in GU Cancer. The 2023 AUA Expert Exchange Podcast: Discussions in GU Cancer is designed to address very specific learning opportunities and reach the urologic practitioners in an easy, flexible way with smaller, targeted updates.

 

 

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from: 

  1. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)
    • Astellas and Pfizer, Inc.
    • AstraZeneca
    • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
    • Lantheus Medical Imaging
    • Merck & Co., Inc.
  2. Treatment Intensification for Advanced Prostate Cancer
    • Astellas and Pfizer, Inc.
    • AstraZeneca
    • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
    • Lantheus Medical Imaging
    • Merck & Co., Inc.
  3. Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer
    • Astellas and Pfizer, Inc.
    • AstraZeneca
    • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
    • Lantheus Medical Imaging
    • Merck & Co., Inc.
  4. Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer
    • AstraZeneca
    • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
    • Lantheus Medical Imaging
    • Merck & Co., Inc.
  5. Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer
    • AstraZeneca
    • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
    • Lantheus Medical Imaging
    • Merck & Co., Inc.
  6. The Latest Breakthroughs in Immunotherapy for GU Cancers
    • AstraZeneca
    • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
    • Lantheus Medical Imaging
    • Merck & Co., Inc.
  7. Germline Testing in GU Cancers – How I Do It
    • AstraZeneca
    • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
    • Lantheus Medical Imaging
    • Merck & Co., Inc.
  8. Novel Imaging for Genitourinary Cancers – Diagnostics and Theranostics
    • Astellas and Pfizer, Inc.
    • AstraZeneca
    • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
    • Lantheus Medical Imaging
    • Merck & Co., Inc.

CME AVAILABLE: https://auau.auanet.org/node/39445

Release Date: November, 2023
Expiration Date: December, 2024

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates these enduring materials for a maximum of 4.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.